

News from the

**U.S. Senate Committee on
Health, Education, Labor and Pensions**

Michael B. Enzi (Wyoming), Chairman



For Immediate Release

Contact: Craig Orfield 202.224.6770

Friday February 17, 2006

***ENZI: BACKLOG OF GENERIC DRUG APPLICATIONS CAUSE
FOR CONCERN; WILL EXAMINE WAYS TO REDUCE DELAYS***

Washington, D.C. - U.S. Sen. Mike Enzi (R-WY), Chairman of the Senate Health, Education, Labor and Pensions Committee (HELP Committee) today issued the following statement concerning the FDA's review and approval of generic drugs:

“Generic drugs are a powerful tool to reduce prescription drug spending. The significant backlog of generic drug applications awaiting action at FDA is cause for concern, and I am interested in examining approaches to reducing that backlog,” Enzi said. “However, it is critical that any initiatives in this area not disrupt the balance between incentives to innovate and incentives for less expensive generics.”

Enzi noted that the HELP Committee is beginning work to reauthorize several important bills dealing with prescription drugs, including the Prescription Drug User Fee Act (PDUFA). “I look forward to discussing generic drugs with the FDA, the brand and generic drug industries, and others as we continue working on this issue,” he added.

###